Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Low-Dose Cyclophosphamide in Recurrent Ovarian Cancer
NCT00072566Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2003
- Primary completion
- Nov 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in ovarian epithelial cancer and primary peritoneal carcinoma (PPC), sponsored by National Cancer Institute. Primary endpoint: Median Time to Progression up to 3 years. Started Dec 2003; status: completed.
02
Drugs
bevacizumab
03
Conditions
ovarian epithelial cancerprimary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT00072566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00072566.